Terns Pharmaceuticals to Host Conference Call to Discuss Top-line Results from Phase 2a LIFT Study of TERN-101 for Treatment ...
June 13 2021 - 5:00PM
Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq:
TERN), a clinical-stage biopharmaceutical company developing a
portfolio of small-molecule single-agent and combination therapy
candidates for the treatment of non-alcoholic steatohepatitis
(NASH) and other chronic liver diseases, announced that the Company
will host a conference call and live webcast on Monday, June 14,
2021 at 8:30 a.m. ET (5:30 a.m. PT) to discuss new top-line data
from the Phase 2a LIFT study evaluating TERN-101 in patients with
NASH. Webcast and conference call details are as follows:
Webcast link:
https://edge.media-server.com/mmc/p/2gsxxmta
Live Conference CallDomestic Callers
(U.S./Canada toll-free): (833) 665-0612International Callers: (929)
517-0403Conference ID: 7587739
Following the live audio webcast, a replay will be available on
the investors page of the Terns Pharmaceuticals website at
http://ir.ternspharma.com for 30 days.
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company developing a portfolio of small-molecule
single-agent and combination therapy candidates for the treatment
of non-alcoholic steatohepatitis, or NASH, and other chronic liver
diseases. Terns’ programs are based on clinically validated and
complementary mechanisms of action to address the multiple hepatic
disease processes of NASH in order to drive meaningful clinical
benefits for patients. For more information, please visit
www.ternspharma.com.
Contacts for Terns:
Investors Justin Ng
investors@ternspharma.com
Media Jenna Urban Berry & Company Public
Relations media@ternspharma.com
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From Apr 2023 to Apr 2024